01 June 2006
An assessment of downward trends in neurodevelopmental disorders in the United States following removal of thimerosal from childhood vaccines.
David A. Geier, Mark R. GeierMed Sci Monit 2006; 12(6): CR231-239 :: ID: 451248
Abstract
Background: The US is in the midst of an epidemic of neurodevelopmentaldisorders (NDs). Thimerosal is an ethylmercury-containing compound added to some childhood vaccines.Several previous epidemiological studies conducted in the US have associated Thimerosal-containing vaccine(TCV) administration with NDs. Material/Methods: An ecological study was undertaken to evaluate NDs reportedto the Vaccine Adverse Event Reporting System (VAERS) from 1991 through 2004 by date of receipt and bydate of vaccine administration. The NDs examined included autism, mental retardation, and speech disorders.Statistical trend analysis was employed to evaluate the effects of removal of Thimerosal on the proportionof NDs reported to VAERS. Results: There was a peak in the proportion of ND reports received by VAERSin 2001-2002 and in the proportion of ND reports by date of vaccine administration in 1998. There weresignificant reductions in the proportion of NDs reported to VAERS as Thimerosal was begun to be removedfrom childhood vaccines in the US from mid-1999 onwards. Conclusions: The present study provides thefirst epidemiological evidence showing that as Thimerosal was removed from childhood vaccines, the numberof NDs has decreased in the US. The analysis techniques utilized attempted to minimize chance or bias/confounding.Additional research should be conducted to further evaluate the relationship between TCVs and NDs. Thisis especially true because the handling of vaccine safety data from the National Immunization Programof the CDC has been called into question by the Institute of Medicine of the National Academy of Sciencesin 2005.
Keywords: Child, Preschool, Child Development Disorders, Pervasive - epidemiology, Preservatives, Pharmaceutical - toxicity, Thimerosal - toxicity, United States, Vaccines - adverse effects
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...Med Sci Monit In Press; DOI: 10.12659/MSM.943797
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952